hypoactive sexual desire disorder Archives

FDA Approves New Treatment for HSDD in Premenopausal Women

by PEPID Newsroom | Jun 21, 2019 | Alerts

FDA approves bremelanotide (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...

FDA Approves New Treatment for HSDD in Premenopausal Women

Recent Posts

Categories